Clinical Trials Browser

NIH × Salts × Endocrine × Clear all

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 1 Completed

CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary